- Conditions
- Acute Kidney Injury
- Interventions
- SCD
- Device
- Lead sponsor
- SeaStar Medical
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 21 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2209–2232
of 11,344
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypereosinophilic Syndrome
- Interventions
- Benralizumab, Placebo
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 130 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 8
- States / cities
- La Jolla, California • Atlanta, Georgia • Bethesda, Maryland + 5 more
- Conditions
- Infant, Newborn, Infant, Moderate Preterm
- Interventions
- Not listed
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- 29 Weeks to 33 Weeks
- Enrollment
- 7,057 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more
- Conditions
- Contraception
- Interventions
- Home Visit, Office visit
- Procedure
- Lead sponsor
- Case Western Reserve University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Externalized Conductors, Visual Lead Anomalies, Electrical Dysfunction
- Interventions
- Implanted with one or more of the following SJM leads: Riata leads, RiataST leads, Durata leads, and QuickSite/QuickFlex leads
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 37 more
- Conditions
- Post Abdominal Surgery Pain
- Interventions
- CR845 IV 1 mcg/kg, CR845 IV 0.5 mcg/kg, Placebo IV
- Drug
- Lead sponsor
- Cara Therapeutics, Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 451 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 23
- States / cities
- Sheffield, Alabama • New Haven, Connecticut • Bradenton, Florida + 20 more
- Conditions
- Epilepsy, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Depression
- Interventions
- TIME
- Behavioral
- Lead sponsor
- Case Western Reserve University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- HIV, Lipodystrophy
- Interventions
- Dual-energy X-ray absorptiometry
- Diagnostic Test
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Biospecimen Collection, Bone Marrow Biopsy, Clinical Observation, Echocardiography Test, Nivolumab
- Procedure · Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Duarte, California + 34 more
- Conditions
- Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized, Myasthenia Gravis
- Interventions
- Efgartigimod IV, Placebo IV
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Fresno, California • Boca Raton, Florida + 15 more
- Conditions
- Cystic Fibrosis, CF, Lung Infection, Pseudomonas Aeruginosa
- Interventions
- Aztreonam for Inhalation (AI), Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Orange, California • San Diego, California + 17 more
- Conditions
- Wound
- Interventions
- MolecuLight i:X Imaging Device
- Device
- Lead sponsor
- MolecuLight Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 367 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Pembroke Pines, Florida • Athens, Georgia + 11 more
- Conditions
- COVID-19
- Interventions
- Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Chicago, Illinois • Mount Pleasant, Michigan + 4 more
- Conditions
- Obesity, Overweight
- Interventions
- Orforglipron, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 50
- States / cities
- Tucson, Arizona • Loma Linda, California • Los Angeles, California + 39 more
- Conditions
- Macular Telangiectasia Type 2 (MacTel)
- Interventions
- NT-501, Sham Procedure
- Combination Product · Procedure
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 16
- States / cities
- La Jolla, California • Los Angeles, California • Palo Alto, California + 13 more
- Conditions
- Breast Cancer
- Interventions
- Radiation, No Radiation
- Radiation · Other
- Lead sponsor
- Canadian Cancer Trials Group
- Network
- Eligibility
- 35 Years and older · Female only
- Enrollment
- 2,138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 451
- States / cities
- Fairbanks, Alaska • Gilbert, Arizona • Phoenix, Arizona + 349 more
- Conditions
- Graft Versus Host Disease
- Interventions
- medical chart review, quality-of-life assessment
- Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Rochester, Minnesota • Cleveland, Ohio + 1 more
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Durvalumab, Echocardiography Test, Iadademstat, Magnetic Resonance Imaging, Multigated Acquisition Scan
- Biological · Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 43
- States / cities
- Duarte, California • Irvine, California • La Jolla, California + 37 more
- Conditions
- Cholecystitis, Acute
- Interventions
- AXIOS(TM) Stent and Electrocautery Enhanced Delivery System
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Fort Wayne, Indiana + 3 more
- Conditions
- Cost Sharing, Acute Coronary Syndrome
- Interventions
- Study voucher card
- Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 11,001 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 271
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 224 more
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Lung Non-Small Cell Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage I Ovarian Cancer AJCC v8, Stage IA Ovarian Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage IB Ovarian Cancer AJCC v8, Stage IC Ovarian Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIA Ovarian Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIB Ovarian Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8
- Interventions
- Chemotherapy, Functional Assessment, Questionnaire Administration
- Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 1,336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 166
- States / cities
- Antioch, California • Dublin, California • Fremont, California + 132 more
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- Radafaxine
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 546 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 29
- States / cities
- Little Rock, Arkansas • Newport Beach, California • Farmington, Connecticut + 25 more
- Conditions
- Dyslipidemia
- Interventions
- PPAR alpha, placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 54
- States / cities
- Hoover, Alabama • Fayetteville, Arkansas • San Diego, California + 51 more
- Conditions
- Breast Cancer
- Interventions
- Sapanisertib, Fulvestrant, Exemestane
- Drug
- Lead sponsor
- Calithera Biosciences, Inc
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 30
- States / cities
- Los Angeles, California • San Francisco, California • Santa Barbara, California + 24 more